NCT06105710Recruiting
Mechanistic Insights From Bronchoscopy Airway Samples
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to examine the mechanisms of asthma. The investigators are comparing the cells of individuals with and without asthma and looking at the roles various parts of the cell play in the production and secretion of mucus.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 24 (estimated)
- First submitted
- 23 Oct 2023
- Start date
- 1 Jul 2024
- Primary completion date
- Dec 2027
- Lead sponsor
- University of California, San Francisco
- Diseases
- Asthma
- NCT number
- NCT06105710
What you commit to
- Study type: Observational
- Planned participants: 24
- From 1 Jul 2024 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects with a history of prior esophageal hernia surgery
- Current participation in an investigational drug trial
- Prohibited Medications and Treatments The following medications are prohibited during the study and must be discontinued prior to enrollment for the amount of time specified below.
- Steroids (oral, inhaled or nasal): 6 weeks
- Omalizumab: 6 months
- Medications to be withheld prior to bronchoscopy: Aspirin or Non- steroidal anti-inflammatory agents (NSAIDs) for 2 days Medications to be withheld before each clinic visit: Short-acting bronchodilators (e.g. Albuterol) for 6 hours; Short-acting anti- cholinergics (e.g. Atrovent, Combivent) for 8 hours; and antihistamines (e.g. Benadryl, Claritin) for 3 days.
Other illness
- Subjects with a history of lung disease other than asthma
- Subjects with a history of a medical disease, which in the opinion of the Investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study
Lab values
- Nedocromil sodium, sodium cromoglycate: 4 weeks
Other
- The same exclusion criteria will apply to both Sub-studies.
- Current smokers, defined by (a) \>5 cigarettes smoked in past 12 months, and (b) ≤ 8 weeks since last time smoking; or former smokers who have a total smoking history
- 10 pack-years
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- Astemizole: 12 weeks
- Long-acting methylxantines: 2 days
- Short-acting methylxantines: 12 hours
- Montelukast: 7 days
- Zafirlukast: 7 days
- Salmeterol: 2 days
Who the study is looking for
- Healthy Controls
- Male and female subjects between the ages of 18 and 70 years
- Ability to provide written informed consent and ability to comply with the requirements of the study
- No hyperreactivity to methacholine (PC20 FEV1 Methacholine \>16 mg/mL)
- No history of allergic rhinitis/seasonal allergies
- Asthmatics
- Male and female subjects between the ages of 18 and 70 years
- Ability to provide written informed consent and ability to comply with the requirements of the study
- History of asthma
- No use of oral or inhaled corticosteroids for the treatment of asthma during the past 6 weeks
- Hyperreactivity to methacholine (PC20 FEV1 Methacholine \< 8 mg/ml)
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.